Go Pro
OTCMKTS:RADLY

Raia Drogasil Q2 2026 Earnings Report

Raia Drogasil logo
$3.41 +0.02 (+0.62%)
As of 02:04 PM Eastern

Raia Drogasil EPS Results

Actual EPS
$0.05
Consensus EPS
$0.05
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Raia Drogasil Revenue Results

Actual Revenue
$2.17 billion
Expected Revenue
$2.32 billion
Beat/Miss
Missed by -$148.75 million
YoY Revenue Growth
N/A

Raia Drogasil Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Raia Drogasil's next earnings date is estimated for Tuesday, November 3, 2026, based on past reporting schedules.

Conference Call Resources

Raia Drogasil Earnings Headlines

Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwide. The analyst, who called the 2020 crash early, is working with a former NSA codebreaker and Pentagon insider on a new approach to AI stocks ahead of August 31. Investors like Stephen and Keith W. say the tools helped shape their portfolios, though results vary and are not typical.tc pixel
See More Raia Drogasil Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Raia Drogasil? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Raia Drogasil and other key companies, straight to your email.

About Raia Drogasil

Raia Drogasil (OTCMKTS:RADLY) is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.

The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades. Headquartered in São Paulo, Raia Drogasil has expanded its footprint to all regions of Brazil, with a particularly strong presence in the Southeastern and Northeastern states. This broad geographic coverage positions the company to capture growth in densely populated metropolitan markets as well as emerging local communities.

In response to evolving consumer preferences, Raia Drogasil has developed digital platforms that support online ordering, home delivery and click-and-collect services. The company has also launched a loyalty program that rewards frequent shoppers with discounts, personalized promotions and health-oriented content. These initiatives complement its physical retail network, enhancing customer convenience and fostering deeper engagement.

Raia Drogasil continues to invest in supply chain optimization and partnerships with pharmaceutical and consumer goods suppliers to broaden its product portfolio. The company’s management emphasizes operational efficiency, store modernization and the integration of digital tools, aiming to reinforce its position as Brazil’s foremost pharmacy chain and to meet the evolving needs of Brazilian consumers.

View Raia Drogasil Profile